Tradegate
13.04.26 | 17:07
23,660 Euro
+0,51 % +0,120
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 23,360 | 23,720 | 13.04. | |
| 23,380 | 23,700 | 13.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDINCELL Aktie jetzt für 0€ handeln | |||||
| 26.03. | EIB Waives its Right to Cash Settlement on Medincell Warrants | 390 | Business Wire | The European Investment Bank (EIB) has waived the put option attached to the warrants granted in connection with the €40 million financing agreement signed in 2022 This waiver eliminates any... ► Artikel lesen | |
| 06.03. | Medincell nimmt 48 Millionen Euro über Privatplatzierung ein | 1 | Investing.com Deutsch | ||
| 06.03. | Medincell raises €48 million in private placement | 1 | Investing.com | ||
| 06.03. | Medincell Announces Successful c. €48 Million Private Placement | 352 | Business Wire | Success of the transaction with €48 million raised. Participation of leading international Healthcare specialist investors. Funds raised are expected to support long-term value creation, primarily... ► Artikel lesen | |
| 05.03. | Medincell startet Privatplatzierung über 6 % des Grundkapitals | 9 | Investing.com Deutsch | ||
| 05.03. | Medincell launches private placement for 6% of share capital | 1 | Investing.com | ||
| 05.03. | Medincell Launches a Private Placement for International Institutional Investors | 512 | Business Wire | The Private Placement, of approximately 6% of the Company's share capital, is aimed at international institutional investors, through an accelerated book-building process. Funds raised are expected... ► Artikel lesen | |
| 04.03. | Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 - 11, 2026 | 402 | Business Wire | Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation... ► Artikel lesen | |
| 24.02. | Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026 | 386 | Business Wire | Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced... ► Artikel lesen | |
| 21.02. | Teva, Medincell granted FDA review for long-acting antipsychotic | 16 | Seeking Alpha | ||
| 21.02. | FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment | 1.092 | AFX News | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration... ► Artikel lesen | |
| 20.02. | Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults | 866 | Business Wire | Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help... ► Artikel lesen | |
| 10.02. | Medincell's ISS ESG Corporate Rating Upgraded | 419 | Business Wire | Medincell's overall ESG rating has been upgraded from C+ to B by ISS, a leading global provider of sustainability ratings Medincell is ranked in the first decile of the Pharmaceuticals Biotechnology... ► Artikel lesen | |
| 28.01. | Medincell - UZEDY: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) | 482 | Business Wire | OLANZAPINE LAI: EU Submission Expected in Q2 2026
Regulatory News:
Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication... ► Artikel lesen | |
| 20.01. | Medincell: Half-year Liquidity Contract Statement | 385 | Business Wire | Regulatory News:
Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at December 31, 2025:... ► Artikel lesen | |
| 12.01. | Medincell: Publication of the 2026 Financial Calendar | 476 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Event Date
Annual results 2025-2026
(April 2025-March 2026)
Tuesday, June 16, 2026
General Meeting
Thursday... ► Artikel lesen | |
| 09.12.25 | Medincell: Starkes Umsatzwachstum, doch anhaltende Verluste belasten den Aktienkurs | 4 | Investing.com Deutsch | ||
| 09.12.25 | Medincell Publishes its Consolidated Half-Year Financial Results | 559 | Business Wire | (April 1st, 2025 September30, 2025)
Regulatory News:
Christophe Douat, CEO of Medincell (Paris:MEDCL)"We are pleased with the company's growth and momentum. We have entered the most transformative... ► Artikel lesen | |
| 09.12.25 | Medincell's Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults | 590 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad... ► Artikel lesen | |
| 01.12.25 | Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025 | 488 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025)
Meeting in French, 6:00... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,30 | +0,06 % | Biotech-Werte im Check: Warum Bioxyne, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| EVOTEC | 4,700 | +3,75 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| MEDIGENE | 0,025 | -19,61 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,350 | +0,87 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,000 | -0,23 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,078 | +23,81 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,657 | +0,42 % | Valneva im freien Fall: Warum erfahrene Anleger heute die Reißleine ziehen - Meine klare Einschätzung dazu | ||
| AMGEN | 296,10 | -0,45 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| NOVAVAX | 6,910 | +0,29 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 295,40 | +0,03 % | Stryker To Buy Amplitude Vascular Systems | WASHINGTON (dpa-AFX) - Stryker Corporation (SYK), a medical technology company, said on Monday that it has signed a deal to buy Amplitude Vascular Systems, Inc., a privately held developer of... ► Artikel lesen | |
| BIOGEN | 148,80 | -0,83 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,660 | +3,91 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,730 | +0,74 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| ILLUMINA | 106,74 | -1,11 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| ERASCA | 16,310 | 0,00 % | Jefferies reiterates Erasca stock Buy rating on rival trial data |
Das Unternehmen MEDINCELL SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 23,660 Euro und damit +0,51 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDINCELL SA finden Sie auf Wallstreet Online.